{"title": "Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)", "doi": "10.1101/2020.02.03.20020248", "citation_id": "2020.02.03.20020248v2", "date": "2020-02-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.03.20020248", "abstract": "<p>A total of 565 Japanese citizens were evacuated from Wuhan, China to Japan. All passengers were screened for symptoms and also undertook reverse transcription polymerase chain reaction testing, identifying 5 asymptomatic and 7 symptomatic passengers testing positive for 2019-nCoV. We show that the screening result is suggestive of the asymptomatic ratio at 41.6%.</p>", "twitter_description": "A total of 565 Japanese citizens were evacuated from Wuhan, China to Japan. All passengers were screened for symptoms and also undertook reverse transcription polymerase chain reaction testing, identifying 5 asymptomatic and 7 symptomatic passengers testing positive for 2019-nCoV. We show that the screening result is suggestive of the asymptomatic ratio at 41.6%.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; R.K.: 18J21587], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413]. NML receive graduate study scholarship from the Ministry of Education, Culture, Sports, Science and Technology, Japan. \n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe data are available in the main text.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20020248v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20020248v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.03.20020248v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.03.20020248.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.03.20020248v2", "access_rights": "restricted", "authors": ["Hiroshi Nishiura", "Tetsuro Kobayashi", "Takeshi Miyama", "Ayako Suzuki", "Sungmok Jung", "Katsuma Hayashi", "Ryo Kinoshita", "Yichi Yang", "Baoyin Yuan", "Andrei R. Akhmetzhanov", "Natalie M Linton"]}